A
Power Law company profile
Aurinia Pharmaceuticals
Biotech & Life Sciences · Edmonton, Canada · Founded 1993 · IPO 1996 Unicorn
Valuation
$1.66B
Market cap · Apr/2026
Revenue
$283M
Latest reported FY
Global footprint
Where Aurinia Pharmaceuticals has talent and traffic
Web traffic by country
5.6K
monthly visits
across markets
across markets
🇺🇸 United States75%
🇨🇦 Canada64.3%
🏳️ Korea5.4%
🏳️ Republic of0%
Patent intelligence
$136M patent portfolio · 66 active families
Total estimated portfolio value via Dealroom Patent Intelligence (Patsnap), with quality scores compared against same-sector peers.
Estimated portfolio value
$136M
8.2% of market cap · 2.6× smaller than top peer Reata Pharmaceuticals ($354M)
66 active patent families
Where Aurinia Pharmaceuticals innovates
Medicinal chemistryPharmaceutical drugPharmacologyDrugIron complex
Below peer median on Legal, Market
Quality vs same-sector peers
Aurinia Pharmaceuticals on the five Patsnap quality dimensions
Aurinia Pharmaceuticals in orange. Same-sector peers are the top filers by total patent value. All scores 0–100; higher is stronger.
Compare against
Patent quality scores (0–100)
Source: Dealroom Patent Intelligence · PatsnapTech-focus vs peers
Where Aurinia Pharmaceuticals concentrates inside the peer cluster
Axes are the most-shared Patsnap topics across Aurinia Pharmaceuticals and its top peers. Each polygon's reach on an axis = how prominent that topic is in that company's portfolio (#1 topic = 100, #10 = 10, absent = 0).
Compare against
Top-topic prominence (rank inverted, 0–100)
Source: Dealroom Patent Intelligence · Patsnap top-10 topics per companySee Aurinia Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.